U.S. patent number RE42,461 [Application Number 12/797,341] was granted by the patent office on 2011-06-14 for hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents. This patent grant is currently assigned to Schering Corporation. Invention is credited to Duane A. Burnett, John W. Clader, Sundeep Dugar, Brian A. McKittrick, Stuart B. Rosenblum.
United States Patent | RE42,461 |
Rosenblum , et al. | June 14, 2011 |
Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4-substituted aryl; Ar.sup.3 is aryl or R.sup.5-substituted aryl; X, Y and Z are --CH.sub.2--, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6R.sup.7; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sub.5, --CF.sub.3, --CN, --NO.sub.2 and halogen R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5OR.sup.6, --O(CO)NR.sup.6R.sup.7, --NR.sub.6R.sup.7, --NR.sup.6(CO)R.sup.7, --NR.sup.6(CO)OR.sup.9, --NR.sup.6(CO)NR.sup.7R.sup.8, --NR.sup.6SO.sub.2R.sup.9, --COOR.sup.6, --CONR.sup.6R.sup.7, --COR.sup.6, --SO.sub.2NR.sup.6R.sup.7, S(O).sub.0-2R.sup.9, --O(CH.sub.2).sub.1-10--COOR.sup.6, --O(CH.sub.2).sub.1-10CON.sup.6R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl or aryl-substituted Ic R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
Inventors: | Rosenblum; Stuart B. (West Orange, NJ), Dugar; Sundeep (San Jose, CA), Burnett; Duane A. (Bernardsville, NJ), Clader; John W. (Milton, VT), McKittrick; Brian A. (New Vernon, NJ) |
---|---|
Assignee: | Schering Corporation
(Kenilworth, NJ) |
Family ID: | 26799377 |
Appl. No.: | 12/797,341 |
Filed: | September 14, 1994 |
PCT Filed: | September 14, 1994 |
PCT No.: | PCT/US94/10099 |
371(c)(1),(2),(4) Date: | March 18, 1996 |
PCT Pub. No.: | WO95/08532 |
PCT Pub. Date: | March 30, 1995 |
Application Number | Filing Date | Patent Number | Issue Date | ||
---|---|---|---|---|---|
Reissue of: | 09594996 | Jun 15, 2000 | Re. 37721 | May 28, 2002 | |
Reissue of: | 08617751 | Mar 18, 1996 | 5767115 | Jun 16, 1998 | |
Current U.S. Class: | 514/210.02; 540/200 |
Current CPC Class: | A61P 7/00 (20180101); A61K 31/35 (20130101); A61P 9/10 (20180101); C07D 205/08 (20130101); A61K 31/21 (20130101); A61P 3/06 (20180101); A61K 9/2018 (20130101); A61K 31/40 (20130101); A61K 31/395 (20130101); A61K 9/4858 (20130101); A61K 45/06 (20130101); A61K 31/21 (20130101); A61K 2300/00 (20130101); A61K 31/35 (20130101); A61K 2300/00 (20130101); A61K 31/395 (20130101); A61K 2300/00 (20130101); A61K 31/40 (20130101); A61K 2300/00 (20130101); Y02P 20/55 (20151101); Y10S 514/824 (20130101) |
Current International Class: | C07D 205/08 (20060101); A61P 9/10 (20060101); A61P 3/06 (20060101); A61K 31/395 (20060101) |
Field of Search: | ;540/200 ;514/210,210.02 |
4144232 | March 1979 | Koppel et al. |
4375475 | March 1983 | Willard et al. |
4443372 | April 1984 | Luo et al. |
4479900 | October 1984 | Luo |
4500456 | February 1985 | Spitzer et al. |
4576749 | March 1986 | Zahler et al. |
4576753 | March 1986 | Kamiya et al. |
4595532 | June 1986 | Miller |
4620867 | November 1986 | Luo |
4633017 | December 1986 | Mueller et al. |
4659716 | April 1987 | Villani et al. |
4675399 | June 1987 | Miller |
4680391 | July 1987 | Firestone et al. |
4759923 | July 1988 | Buntin et al. |
4784734 | November 1988 | Torii et al. |
4794108 | December 1988 | Kishimoto et al. |
4803266 | February 1989 | Kawashima et al. |
4806564 | February 1989 | Chabala et al. |
4816477 | March 1989 | Girotra et al. |
4834846 | May 1989 | Abramson et al. |
4847271 | July 1989 | Chabala et al. |
4876365 | October 1989 | Kirkup et al. |
4983597 | January 1991 | Yang et al. |
5030628 | July 1991 | Joyeau et al. |
5099034 | March 1992 | Yoshida et al. |
5120729 | June 1992 | Chabala et al. |
5124337 | June 1992 | Dugar et al. |
5159025 | October 1992 | Terada |
5229381 | July 1993 | Doherty et al. |
5229510 | July 1993 | Knight et al. |
5238950 | August 1993 | Clader et al. |
5306817 | April 1994 | Thiruvengadam et al. |
5348953 | September 1994 | Doherty et al. |
5350868 | September 1994 | Yoshida et al. |
5412092 | May 1995 | Rey et al. |
5550229 | August 1996 | Iwasaki et al. |
5576470 | November 1996 | Tuller et al. |
5595997 | January 1997 | Aberg et al. |
5624920 | April 1997 | McKittrick et al. |
5631365 | May 1997 | Rosenblum et al. |
5633246 | May 1997 | McKittrick et al. |
5661145 | August 1997 | Davis |
5688785 | November 1997 | Vaccaro |
5688787 | November 1997 | Burnette et al. |
5688990 | November 1997 | Shankar |
5698548 | December 1997 | Dugar et al. |
5728827 | March 1998 | Thiruvengadam et al. |
5739321 | April 1998 | Wu et al. |
5744467 | April 1998 | McKittrick et al. |
5767115 | June 1998 | Rosenblum et al. |
5767126 | June 1998 | Marchbanks |
5817806 | October 1998 | Rossi et al. |
5846966 | December 1998 | Rosenblum et al. |
5847115 | December 1998 | Iwasaki et al. |
5856473 | January 1999 | Shankar |
5925668 | July 1999 | Biewenga et al. |
RE36481 | January 2000 | Inamine et al. |
6372756 | April 2002 | Christians et al. |
6455572 | September 2002 | Day et al. |
6465490 | October 2002 | Bernotas et al. |
6982251 | January 2006 | Ghosal et al. |
1063108 | Sep 1979 | CA | |||
1173837 | Sep 1984 | CA | |||
1213596 | Nov 1986 | CA | |||
1253146 | Apr 1989 | CA | |||
1262357 | Oct 1989 | CA | |||
1267415 | Apr 1990 | CA | |||
1268780 | May 1990 | CA | |||
2004355 | Jun 1990 | CA | |||
2024267 | Mar 1991 | CA | |||
1286304 | Jul 1991 | CA | |||
2052973 | Apr 1992 | CA | |||
2072215 | Dec 1992 | CA | |||
2114007 | Feb 1993 | CA | |||
2152351 | Jul 1994 | CA | |||
1331755 | Aug 1994 | CA | |||
2154257 | Aug 1994 | CA | |||
2172149 | Nov 2000 | CA | |||
2046823 | Mar 1972 | DE | |||
0 199 630 | Oct 1986 | EP | |||
0199630 | Oct 1986 | EP | |||
0 264 231 | Apr 1988 | EP | |||
0264231 | Apr 1988 | EP | |||
0 333 268 | Sep 1989 | EP | |||
0333268 | Sep 1989 | EP | |||
0337 549 | Oct 1989 | EP | |||
0337549 | Oct 1989 | EP | |||
0 365 364 | Apr 1990 | EP | |||
0365364 | Apr 1990 | EP | |||
0 401 705 | Dec 1990 | EP | |||
0 415 487 | Mar 1991 | EP | |||
0415487 | Mar 1991 | EP | |||
0 462 667 | Dec 1991 | EP | |||
0462667 | Dec 1991 | EP | |||
0 481 671 | Apr 1992 | EP | |||
0481671 | Apr 1992 | EP | |||
508 425 | Oct 1992 | EP | |||
0 524 595 | Jan 1993 | EP | |||
524 595 | Jan 1993 | EP | |||
0524595 | Jan 1993 | EP | |||
0720599 | Jul 1996 | EP | |||
8-505141 | Apr 1996 | JP | |||
WO87/04429 | Jul 1987 | WO | |||
WO93/02048 | Feb 1993 | WO | |||
WO 94/06784 | Mar 1994 | WO | |||
WO94/17038 | Apr 1994 | WO | |||
WO94/14433 | Jul 1994 | WO | |||
WO94/17036 | Aug 1994 | WO | |||
WO94/17038 | Aug 1994 | WO | |||
WO 94/19351 | Sep 1994 | WO | |||
WO95/08532 | Mar 1995 | WO | |||
WO01/32161 | May 2001 | WO | |||
Allain et al., Enzymatic Determination of Total Serum Cholesterol, Clinical Chemical 20:470-475 (1974). cited by other . Baxter, Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in vivo, Journal of Biological Chemistry 267:11705-11708 (1992). cited by other . Burrier et al., The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine, The Journal of Pharmacology and Experimental Therapeutics 272:156-163 (1994). cited by other . Burrier et al., Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster, Biochemical Pharmacology 47:1545-1551 (1994). cited by other . Clader et al., Substituted (1,2-Diarylethyl)amide Acy-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity, Journal of Medicinal Chemistry 38:1600-1607 (1995). cited by other . Durst et al., Metallation of N-Substituted .beta.-Lactams, A Method for the Introduction of 3-Substituents into .beta.-Lactams, Canadian Journal of Chemistry, 50:3196-3201 (1971). cited by other . Georg et al., 3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines, Tetrahedron Letters 26(33):3903-3906 (1985). cited by other . Hart et al., An Enantioselective Approach to Carbapenen Antibodies: Formal Synthesis of (+)-Thienamycin, Tetrahedron Letters, 26(45):5493-5496 (1985). cited by other . Harwood, Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin .beta.-tigogenin cellobioside (CP-88818; liqueside), Journal of Lipid Research 34:377-395 (1993). cited by other . Hoekman et al., Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Add .delta.-Lactones, J. Agric, Food Chem. 30:920-924 (1982). cited by other . Horie et al., Hypolipidemic effects of NB-598 in dogs, Atherosclerosis 88:183-192 (1991). cited by other . Illingworth, An Overview of Lipid-Lower Drugs, Drugs 36:63:71 (1988). cited by other . International Search Report dated Dec. 8, 1994 in PCT/US94/10099. cited by other . Mayrhofer et al., Simple Prep. of 3-Benzylidene-2-azetilidinones, Synthesis 247-8 (1980). cited by other . Nobuki et al., Stereoselective syntheses of .beta.-lactam derivatives by ultrasound promoted Reformatskii reaction, Chemical Abstracts No. 106:17 (1977) Abstract 138174y. cited by other . Otto et al., Stereochemistry of dehydration and halogenation of .alpha.R* and .alpha.S* isomeric 3-(.alpha.-hydroyxbenzy1-1-4-dipheny1=2-azetidinones, Chemical Abstracts 19:99 (1983) Abstract 18083h. cited by other . Panfil et al., Synthesis of .alpha.-Lactams from a,.alpha.-Unsaturated Sugar .delta.-Lactones, Heterocycles 24:1009-1617(1986). cited by other . Ram et al., Potential hypolipidemic agents:Part V.dagger.-Synthesis biological activity of new ethyl 4-(2-oxazetidin-4-yl)phenoxyalkanoatest.dagger-dbl., Indian Journal of Chemistry 29B:1134-1137 (1990). cited by other . Salisbury et al., Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461, Atherosclerosis 115:45-63 (1995). cited by other . Schnitzer-Polokoff et al., Effects of Acyl-CoA:Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters, Comp. Biochem. Physiol. 99A:665-670 (1991). cited by other . Simova, Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline, Chemical Abstracts 15:86 (1977) Abstract 106130h. cited by other . Summary Factfile, May 1992, "Anti-Atherosclerotic Agents" Current Drugs Ltd., pp. A5-A23. cited by other . USAN and the USP dictionary of drug names, U.S. Pharmacopeial Convention, Inc., entries ATEVI-ATRIM, p. 62 (though Jun. 15, 1993). cited by other . USP Dictionary of USAN and International Drug Names, U.S. Pharmacopeial Convention, Inc., entries AT-101-ATORV, p. 62 (though Jun. 15, 1994). cited by other . Witztum, Current Approaches to Drug Therapy for the Hypercholesterolemic Patient, Circulation 80:1101-1114 (1989). cited by other . Written Opinion dated May 16, 1995 in PCT/US94/10099. cited by other . U.S. Appl. No. 07/995,488, filed Dec. 12, 1992, Davis. cited by other . U.S. Appl. No. 08/102,440, filed Sep. 21, 1993, Rosenblum. cited by other . "Heart disease" Statistics http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statist- ics.html#heartdiesease .COPYRGT. 2010. cited by other . Abel et al., Cortisol Metabolism by Human Liver in vitro-IV. Metabolism of 9 .alpha.-fluorocortisol by Human Liver Microsomes and Cytosol., J. Steroid. Biochem. Molec. Biol. 46(6):833-839 (1993). cited by other . Abel et al., Cortisol Metabolism by Human Liver in vitro-I Metabolite identification and Inter-Individual Variability, J. Steroid. Biochem. Molec. Biol. 43(7):713-719 (1992). cited by other . Ajmera et al., Synthesis and Biological Activity of 5-Fluoro-2',3'-dideoxy-3'-Fluorouridine and Its 5'-Phosphate, J. Med. Chem. 27(1):11-14 (1984). cited by other . Altmann et al., Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption, Science 303:1201-1204 (2004). cited by other . Altschul et al., Influence of Nicotinic Acid on Serum Cholesterol in Man, Arch Biochem, 54(2):558-559 (1955). cited by other . American Heritage Dictionary of the English language, 2nd College ed., Houghton Mifflin Co.--"appy as remedy" (1985). cited by other . Angelin et al., Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition, Eur. J. Clin. Invest. 16:391-396 (1986). cited by other . Anitschkow and Chalatow, On Experimental Cholesterin Steatosis and Its Significance in the Origin of Some Pathological Processes, Arteriosclerosis 3(2):178-182 (1983). cited by other . Augelli-Szafran et al., Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel .alpha.-ketoamides as hypocholesterolemic agents, J. Med. Chem. 36(20):2943-2949 (1993). cited by other . Austel and Kutter, Quant. Struct. Activity Relationships of Drugs, John G. Toplissm (ed.), Academic Press, pp. 437-496 (1983). cited by other . Bannai et al., Synthesis of Chemically Stable Prostacyclin Analogs, Tetrahedron 39(22):3807-3819 (1983). cited by other . Barnard et al., The Effect of Fluorine Substitution on the Physicochemical Properties and the Analgesic Activity of Paracetamol, J. Pharm. Pharmacol. 45(8):736-744 (1993). cited by other . Bass et al., Effect of Ring Fluorination of Epinephrine on Its Cardiovascular Adrenoceptor Activities, Eur. J. Pharmacol. 187(1):87-95 (1990). cited by other . Bergstrom and Shum, Synthesis and Characterization of a New Fluorine Substituted Nonionic Dinucleoside Phosphonate Analogue, P-Deoxy-P-(difluoromethyl)thymidyly1(3'-> 5')thymidine, J. Org. Chem. 53:3953-3958 (1988). cited by other . Bergstrom et al., 3',3'-Difluoro-3'-Deoxythymidine:Comparison of Anti-HIV Activity to 3'-Fluoro-3'-Deoxythymidine, J. Med. Chem. 35(18):3369-3372 (1992). cited by other . Bergstrom et al., Fluorine Substituted Analogs of Nucleosides and Nucleotides, Nucleos, Nucleot. 6(1 & 2):53-63 (1987). cited by other . Bey et al., Further Studies on the Inhibition of Monoamine Synthesis by Monofluoromethyldopa, Br. J. Pharmacol, 70(4):571-576(1980). cited by other . Black et al., Modulation of Carcinogenicity in 1,2, 3, 4-Tetrahydro-7,12-Dimethylbenz[a] Anthracene (THDMBA) by Fluorine Substitution: Crystal Structures of the 5- and 6- Fluoro Regioisomers, Carcinogenesis 13(8):1337-1343 (1992). cited by other . Blackburn et al., Isopolar vs isosteric Phosphonate Analogues of Nucleotides, Nucleos. Nucleot. 4(1 & 2):165-167 (1985). cited by other . Blackburn, Overview: The Seven Countries Study in Brief, http://www.epi.umn.edu/research/7countries/overview/shtm, downloaded on Aug. 10, 2010. cited by other . Blankenhorn and Hodis, Treating serum lipid abnormalities in high-priority patients, Postgrad. Med., 89(1):81-96 (1991). cited by other . Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (Abstract only). cited by other . Braun and Galle, A simple stereoselective synthesis of cholestrol absorption inhibitor (--)- SCH 48461, Synthesis 7:819-820 (1996). cited by other . Bravo et al., Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoromuscarines, J. Med. Chem. 35(17):3102-3110 (1992). cited by other . Brockman et al., Metabolism and Chemotherapeutic Activity of 9-.beta.-D-Arabinofuranosyl-2-Fluoroadenine against Murine Leukemia L1210 and Evidence for Its Phosphorylation by Deoxycytidine Kinase, Cancer Res. 40(10):3610-3615 (1980). cited by other . Brodbeck et al., Fluorinated Aldehydes and Ketones Acting as Quasi-Substrate Inhibitors of Acetylcholinesterase, Biochim. Biophys. Acta. 567(2):357-369 (1979). cited by other . Brooks and Wiley, Evolution as Entropy. Towards a Unified Theory of Biology, D.L. Hull (editor) Second Edition (University of Chicago Press), Table of Contents (1968). cited by other . Brown and Bowden, New Twists on an Old Theme, Chem. Ind. 5:143-147 (1993). cited by other . Brown, Review of Clinical Studies of Fenofibrate in Combination with Currently Approved Lipid-Lowering Drugs, Cardiology 76(1):45-54 (1989). cited by other . Buffa and Peters, The in vivo Formation of Citrate Induced by Fluoroacetate and Its Significance, J. Physiol. 110(3-4):488-500 (1950). cited by other . Bugrim, "Early Prediction of Drug Metabolism and Toxicity: Systems Biology Approach and Modeling," Drug Discovery Today 9(3):127-135 (2004). cited by other . Buhler et al. Metabolism and Tumorigenicity of 7-, 8-,9-, and 10-Fluorobenzo(a) Pyrenes, Cancer Res. 42(11):4779-4783 (1982). cited by other . Burger, Progress in Drug Research. Fortschritte der Arneimittelforschung Progres des rescherches pharmaceutiques, Prog. Drug. Res. 37:287-371 (1991). cited by other . Burnett and Davis, "Chapter 6. Recent Advances in the Science and Treatment of Atherosclerosis," Annual Reports In Med. Chem., vol. 36, pp. 57-66 (Greenlee, Ed.), Academic Press (2001). cited by other . Burnett at al., 2-Azetidinones as Inhibitors of Cholesterol Absorption, J. Med. Chem. 37(12):1733-1736 (1994). cited by other . Burnett et al., Synthesis of Iodinated Biochemical Tools Related to the 2-Azetidinone Class of Cholesterol Absorption Inhibitors, Biorg. & Med. Chem. Letters 12:311-314 (2002). cited by other . Burnett, Asymmetric synthesis and absolute stereochemistry of cholesterol absorption inhibitor, SCH 48461, Tet. Letters 35(40):7339-7342 (1994). cited by other . Burnett, .beta.-Lactam Cholesterol absorption inhibitors, Curr. Med. Chem. 11:1873-1887 (2004). cited by other . Burrier et al., The Effect of Acyl CoA: Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine. J. Pharmacol. Exp. Ther. 372(1): 156-163 (1995). cited by other . Bush and Mahesh Metabolism of 11-Oxygenated Steroids. 2. 2-Methyl Steroids, Biochem. J. 71(4):718-742 (1959). cited by other . Bush and Mahesh, Metabolism of 11-Oxygenated Steroids. 3. Some 1-Dehydro and 9 .alpha.-fluoro Steroids, Biochem. J. 93(2):236-255 (1964). cited by other . Butler and Gray, The Metabolism of Betamethasone, J. Endocrinol. 46(3):379-390 (1970). cited by other . Campbell et al., .beta.-Lactamase Activity of Purified and Partially Characterized Human Renal Dipeptidase, J. Biol. Chem. 259(23):14586-14590 (1984). cited by other . Carpenter et al., Pharmacokinetics of Inhaled Anesthetics in Humans: Measurements During and After the Simultaneous Administration of Enflurane, Halothane, Isoflurane, Methoxyflurane, and Nitrous Oxide, Anesth. Analg. 65(6):575-582 (1986). cited by other . Carrell et al., Fluorocitrate Inhibition of Aconitase: Relative Configuration of Inhibitory Isomer by X-Ray Crystallography Science 170(965):1412-1414 (1970). cited by other . Cates, Calculation of drug solubilities by pharmacy students, Am. J. Pharm. Ed., 45:11-13 (1981). cited by other . Chen et al., Asymmetric Synthesis of Substituted 2-Azaspiro[3.5]nonan-1-ones: An Enantioselective Synthesis of the Cholesterol Absorption Inhibitor (+)-SCH 54016, J. Org. Chem. 61(23):8341-8343 (1996). cited by other . Chiba et al., Oxidative Metabolism of Omeprazole in Human Liver Microsomes: Cosegregation with S-Mephenytoin 4'- Hydroxylation, J. Pharmacol. Exp. Ther. 266(1):52-59 (1993). cited by other . Clader et al., 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus, J. Med. Chem. 39:3684-3693 (1996). cited by other . Clader, Ezetimibe and other Azetidinone Cholesterol Absorption Inhibitors, Curr. Topics in Med. Chem. 5(3):243-256 (2005). cited by other . Clader, Ezetimibe: Chemistry-Driven Drug Discovery in the Absence of a Defined Molecular Target Schering-Plough Research Institute Visio Presentation (slides) (2005). cited by other . Clader, The Discovery of Ezetimibe: A View from Outside the Receptor, J. Med. Chem. 47(1):1-9 (2004). cited by other . Claudi et al., Synthesis and Dopamine Receptor Affinities of 2-(4-Fluoro-3-Hydroxyphenyl) Ethylamine and N-Substituted Derivatives, J. Med. Chem. 33(9):2408-2412 (1990). cited by other . Curtis et al., Double-blind, placebo-controlled cross-over trial of cholestyramine an bezafibrate in the treatment of monogenic familial hypercholesterolaemia (FH), Atherosclerosis 68:271 (1987). cited by other . Davidson and Eastham, Acute Liver Necrosis Following Overdose of Paracetamol, Br. Med. J. 2(5512):497-499 (1966). cited by other . Davis et al., Species Differences in Hepatic Glutathione. Depletion, Covalent Binding and Hepatic Necrosis After Acetaminophen Life Sci., 14(11):2099-2109 (1974). cited by other . Davis et al., The hypercholesterolemic activity of the potent cholesterol absorption inhibitor SCH 58235 alone and in combination with HMG CoA reductase inhibitors, XII Int'l Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 62 (1995). cited by other . Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3Hydroxy-3Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, Metabolism 50(10):1234-1241 (2001). cited by other . DeBernardis et al., Conformationally Defined Adrenergic Agents. 1. Design and Synthesis of Novel .alpha.2 Selective Adrenergic Agents: Electrostatic Repulsion Based Conformational Prototypes, J. Med. Chem. 28(10):1398-1404 (1985). cited by other . deGennes et al., Long-term (over 5 years) treatment of primary hyperlipidemia by fenofibrate alone or with cholestyramine, Treatment of Hyperlipoproteinemia, (Carlson and Olsson, eds.), Raven Press, NY, pp. 175-180 (1984). cited by other . Dembowski and Davidson, Statin and Ezetimibe Combination Therapy in Cardiovascular Disease. Curr. Opin. Endocrinol. Diabetes Obes. 16(2):183-188 (2009). cited by other . Development of new stereoisomeric drugs, May 1, 1992, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidance- /ucm122883.htm, downloaded Aug. 10, 2010. cited by other . Di Giulio, et al., Encapsulation of Ampicillin in Reverse-Phase Evaporation Liposomes: A Direct Evaluation by Derivative Spectrophotometry, Int. J. Pharm. 74:183-188 (1991). cited by other . Dodd et al., Metabolism and Pharmacokinetics of Selected Halon Replacement Candidates, Toxicol. Lett. 68(1-2):37-47 (1993). cited by other . Doherty et al., Design and Synthesis of Potent, Selective, and Orally Active Fluorine-Containing Renin Inhibitors, J. Med. Chem. 35(1):2-14 (1992). cited by other . Dolle et al., ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Sulfoximine and 3-Hydroxy-.beta.-Lactam Containing Analogues of Citric Acid as Potential Tight-Binding Inhibitors, J. Med. Chem. 35(26):4875-4884 (1992). cited by other . Dorland's Illustrated Medical Dictionary, 30th Ed., W.B. Saunders & Co., Canada, p. 1513 (2003)--"prodrug". cited by other . Drazen et al., Cholesterol Lowering and Ezetimibe, N. Eng. J. Med. 358(14):1507-1508 (2008). cited by other . Drug Information, Baycol Information, Center for Drug Evaluation and Research, 2001, http://www.fda.gov/cder/drug/infopagelbaycol/default.htm, downloaded Apr. 15, 2009. cited by other . Dugar et al., Amides of Piperidine, Morpholine and Piperazine Substituted 1-Phenylethylamines: Inhibitors of AcylCoA:cholesterol Acyltransferase (ACAT) Activity in vitro and in vivo, Bioorg. Med. Chem., 3(9):1231-1236 (1995). cited by other . Dugar et al., Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461, Bioorg. Med. Chem. Lett. 5(24)2947-2952 (1995). cited by other . Dugar et al., Metabolism and structure activity data based drug design; discovery of (-) SCH 53079 an analog of the potent cholesterol absorption inhibitor (-) SCH 48461, Bioorg. Med. Chem. Lett. 6(11):1271-1271 (1996). cited by other . Dugar et al., N-Oleayl-l,2,3,4-Tetrahydroisoquinolines as Conformationally Restricted Inhibitors of Acyl-CoA:Cholesterol Acyl Transferase (ACAT), Bioorg. Med. Chem. Lett., 3(4):571-576 (1993). cited by other . Dugar et al., Substituted 2-Azaspiro[5.3]nonan-1-ones as Potent Cholesterol Absorption Inhibitors: Defining a Binding Conformation for SCH 48461, J. Med. Chem. 38(25):4875-4877 (1995). cited by other . DuJovne et al., Probucol with colestipol in the teatment of hypercholesteolemia, Ann. Intern. Med. 100:477-482 (1984). cited by other . Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (Abstract only). cited by other . Duschinsky et al., The Synthesis of 5-Fluoropyrimidines, J. Am. Chem. Soc. 79:4559-4560 (1957). cited by other . Dysken et al., Fluphenazine Pharmacokinetics and Therapeutic Response, Psychooharmacology 73:205-210 (1981). cited by other . East et al., Combination drug therapy for treatment of patients with familial combined hyperlipidemia resulting in combined hypertriglyceridemia and hypercholesterolemia, Arteriosclerosis 6:544A (1986). cited by other . Eger et al., Is Enfiurane Hepatotoxic? Anesth. Analg. 65(1)21-30 (1986). cited by other . El Masry, Studies in Detoxication. 69. The metabolism of alkylbenzenes: n-propylbenzene and n-butylbenzene with further observations of ethylbenzene, Biochem J. 64(1):50-56 (1956). cited by other . Elliott, The Role of Fluorine in the Development of Central Nervous System Agents in Biomedicinal Aspects of Fluorine Chemistry (R. Fuller and Y. Kobayashi, eds.), Elsevier Biomedical Press, New York, pp. 55-74, (1982). cited by other . Erlenmeye et al., Justus Liebigs Annalen der Chemie, Liepzig, C.F. Wintersche Verladshandluna, pp. 51-123 (1907), vol. 356. cited by other . Filler, Organofluorine Chemicals and their Industrial Applications (Banks, R. E, ed.), Ellis Horwood Ltd. Publishers, Chichester, Ch. 6 Fluorine-containing Drugs (1979). cited by other . Frey and Frey, Urinary 6 .beta.-Hydroxyprednisolone Excretion Indicates Enhanced Prednisolone Catabolism, J. Lab. Clin. Med. 101(4):593-604 (1983). cited by other . Fried and Sabo, 9.alpha.-Fluoro Derivatives of Cortisone and Hydrocortisone, J. Am. Chem. Soc. 76:1455-1456 (1954). cited by other . Fried et al., 10,10-Difluoro-13-Dehydroprostacyclin: A Chemically and Metabolically Stabilized Potent Prostacyclin, J. Med. Chem. 23(3):234-237 (1980). cited by other . Fried et al., Synthesis and Properties of 7,7-Difluoro Derivatives of the 2,6-Dioxa[3.1.1] bicycloheptane Ring System Present in Thromboxane A.sub.2, J. Am. Chem. Soc. 106:3871-3872 (1984). cited by other . Garcia-Calvo et al., The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1), Proc. Natl. Acad. Sci. USA 102(23):8132-8137 (2005). cited by other . Gazi et al., Effect of Ezetimibe in Patients Who Cannot Tolerate Statins or Cannot Get to the Low Density Lipoprotein Cholesterol Target Despite Taking a Statin, Curr. Med. Res. Opin. 23(9):2183-92 (2007). cited by other . Generic Pharmaceutical Association. Facts at a Glance. http://www.gphaonline.org/about-gpha/about-generics/facts .COPYRGT. 2010. cited by other . Georg and Gill, Stereo--and Enantio-controlled synthesis of chiral intermediates for the total synthesis of thienaycin and related .beta.-Lactam antibiotics from 3-hydroxybutyrates, J. Chem. Soc., Chem. Comm. pp. 1433-1435 (1985). cited by other . Georg et al., An Impoved Mehod For The Stereoselective Synthesis Of B-Lactams From Carboxylic Acids And Imines, Tet. Lett. 32(5):581-584(1991). cited by other . Goldstein and Brown, Cholesterol: A Century of Research. HHMI Bulletin, vol. 16, No. 3, Sep. 2003. cited by other . Gootz et al., "Pharmacokinetic Studies in Animals of a New Parenteral Penem CP-65,207 and its Oral Prodrug Ester," J. Antibiot. 43(4):422-432 (1990). cited by other . Gotto, Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease, Circulation 114:1310-1314 (2006). cited by other . Grundy et al., Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in Heterozygous familial hypercholesterolemia, Ann. Intern. Med., 103:339-343 (1985). cited by other . Guengerich and MacDonald, Chemical Mechanism of Catalysis by Cytochromes P-450: A Unified View, Acc. Chem. Res. 17:9-16 (1984). cited by other . Halloran et al., An Examination of the Importance of 24-Hydroxylation to the Function of Vitamin D During Early Development, Endocrinology 108(6):2067-2071 (1981). cited by other . Hansch and Leo, Cluster Analysis and the Design of Congener Sets, in Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley & Sons, NY, Ch. 6, 48-54 (1979). cited by other . Harris and Anders, Metabolism of the Hydrochlorofluorocarbon 1,2-Dichloro-1,1-Difluoroethane, Chem. Res. Toxicol. 4(2):180-186 (1991). cited by other . Harris et al., Pentahaloethane-Based Chlorofluorocarbon Substitutes and Halothane: Correlation of In Vivo Hepatic Protein Trifluoroacetylation and Urinary Trifluoroacetic Acid Excretion with Calculated Enthalpies of Activation, Chem. Res. Toxicol. 5(5):720-725 (1992). cited by other . Harris et al., Tissue Acylation by the Chlorofluorocarbon Substitute 2,2-Dichloro-1,1,1-Trifluoroethane, Proc. Natl. Acad. Sci. USA 88(4):1407-1410 (1991). cited by other . Harrison et al., Metabolic Defluorination of 5-Fluoro-Amodiaquine in the Rat, Br. J. Clin. Pharmacol. 34:148P-149P (1992). cited by other . Hart and Ha, The Ester Enoiate-Imine Condensation Route to .beta.-Lactams, Chem. Rev. 89(7):1447-1465 (1989). cited by other . Hecht et al., Comparative Mutagenicity, Tumor-Initiating Activity, Carcinogenicity, and In Vitro Metabolisrn of Fluorinated 5-Methylchrysenes, J. Natl. Cancer Inst. 63(3):855-861 (1979). cited by other . Hecht et al., Reduction of Tumorigenicity and of Dihydrodiol Formation by Fluorine Substitution in the Angular Rings of Dibenzo(a,i) Pyrene, Cancer Res. 41(11 Pt. 1):4341-4345 (1981). cited by other . Heidelberger et al., Fluorinated Pyrimidines, a New Class of Tumour-Inhibitory Compounds, Nature 179(4561):663-666 (1957). cited by other . Heidelberger, The Nucleotides of Fluorinated Pyrimidines and Their Biological Activities, in Carbon-Fluorine Compounds: Chemistry, Biochemistry and Biological Activities, (K. Elliot, ed.), Associated Scientific Publishers, Amsterdam, pp. 125-140 (1972). cited by other . Herper, Behind Zetia's curtain, http://www.forbes.com/2002/10/31/cx, downloaded Apr. 29, 2010. cited by other . High Blood Cholesterol: What you need to know, http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm--downloaded Aug. 10, 2010. cited by other . Hitt et al., Metabolism of Isoflurane in Fischer 344 Rats and Man, Anesthesiology 40(1):62-67(1974). cited by other . Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) Abstract only. cited by other . Hodgkins and Megarity, A Study of Benzyl Free Radical and Substituted Benzyl Free Radicals, J. Amer. Chem. Soc. 87(23):5322-5326 (1965). cited by other . Hoeg et al., The Effects of Mevinolin and Neomycin Alone and in Combination on Plasma Lipid and Lipoprotein Concentrations in Type II Hyperlipoproteinemia, Atherosclerosis 60:209-214 (1986). cited by other . Hoeg, Combination Drug Therapy, in Drug Treatment of Hyperlipidemia, Ch. 10, (Rifkind, Ed.), Marcel Dekker, Inc., pp. 215-231 (1991). cited by other . Huberman and Slaga, Mutagenicity and Tumor-Initiating Activity of Fluorinated Derivatives of 7,12-Dimethylbenz(a)Anthracene, Cancer Res. 39(2 Pt. 1):411-414 (1979). cited by other . Hughes and Saunders, Enzymatic Rupture of a C-F Bond, Chem. Ind. (London) 1265 (1954). cited by other . Humphrey and Smith, Role of metabolism ad pharmacokinetic studies in the discovery of new drugs--present and future perspectives, Xenobiotica 22(7):743-755 (1992). cited by other . Husain et al., Fluoride Elimination from Substrates in Hydroxylation Reactions Catalyzed by p-Hydroxybenzoate Hydroxylase, J. Biol. Chem. 255(9):4189-4197 (1980). cited by other . Illingworth and Bacon, Hypolipidemic Effects of HMG-CoA Reductase Inhibitors in Patients with Hypercholesterolemia, Am. J. Cardiol. 60(12):33g-42g (1987). cited by other . Illingworth et al., Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia, Lancet 1(8215):296-298 (1981). cited by other . Illingworth et al., Long-Term Experience with HMG-CoA Reductase Inhibitors in the Therapy of Hypercholesterolemia, Atherosclerosis Revs. 18:161-187 (1988). cited by other . Illingworth, Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia, Ann. Intern. Med. 101:598-604 (1984). cited by other . Intelligence.360, Global Pharmaceutical Perspectives, Making sense of the year--and what lies ahead--in a time of unprecedented challenge and opportunity, 2006. cited by other . Jamali, Stereochemically Pure Drugs--An Overview, Drug Stereochemistry, in Analytical Methods and Pharmacology. Ch. 14, pp. 375-384 (1993). cited by other . Jerina et al., Carcinogenicity of Benzo[a]Pyrene, in Drug Design and Adverse Reactions (II. Bundgaard, P. Juul, and H. Kafod, eds.), Academic Press, New York, pp. 261-275 (1977). cited by other . Jeu and Cheng, Pharmacology and Therapeutics of Ezetimibe (SCH 58235), a Cholesterol-Absorption Inhibitor, Clin. Ther. 25(9):2352-2387 (2003). cited by other . Jones et al. Biotransformation and Hepato-Renal Function in Volunteers After Exposure to Desflurane (1-653), Br. J. Anaesth. 64(4):482-487 (1990). cited by other . Kane et al., Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen, New Engl. J. Med. 304(5):251-258 (1981). cited by other . Kastelein et al., Simvastatin with or without ezetimibe in Familial Hypercholesterolemia, New Eng. J. Med. 358(14):1431-43 (2008). cited by other . Kastelein, Statin Therapy with Ezetimibe or Niacin in High-Risk Patients, New Eng. J. Med., 361:2180-2183 (2009). cited by other . Kaufman, The enzymic conversion of 4-fluorophenylalanine to tyrosine, Biochim, Biophys. Acta 51:619-621 (1961). cited by other . Kawase et al., Mechanism of Autoxidation of 5,7-Dihydroxytryptamine: Effect of Fluorine Substitution at Positions 4 and/or 6, Chem. Pharm, Bull 38(11):2939-2946 (1990). cited by other . Kenna et al., Metabolic Basis for a Drug Hypersensitivity: Antibodies in Sera From Patients With Halothane Hepatitis Recognize Liver Neoantigens that Contain the Trifluoroacetyl Group Derived from Halothane, J. Pharmacol. Exp. Ther. 245(3):1103-1109 (1988). cited by other . Kimura et al., Structure-activity relationship of a series of phenylureas linked to 4-phenylimidazole. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity. 2., J. Med. Chem. 36(11):1641-1653 (1993). cited by other . Kimura et al., Structure-Activity Relationship of N-[2-(Dimethylamino)-6-[3-(5-Methy1-4- Phenyl-1H-Imidazol-1-yl)Propoxy]Phenyl]-N'-Pentylurea and Analogues. Novel Potent Inhibitors of Acyl-CoA: Cholesterol O-Acyltransferase with Antiatherosclerotic Activity, J. Med. Chem. 36(11):1630-1640 (1993). cited by other . Kirk et al., Syntheses and adrenergic agonist poperies of ring-fluorinated isoproterenols, J. Med. Chem. 25(6):680-684 (1982). cited by other . Kirk et al., Synthesis and adrenergic activity of ring-fluorinated phenylepherines, J. Med. Chem. 29(10):1982-1988 (1986). cited by other . Kirkup et al., (-)-SCH 57939: Synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor, Bioorg. Med. Chem. Lett. 6(17):2069-2072 (1996). cited by other . Kitteringham et al., Conjugation of dinitrofluorobenzene to plasma proteins in vivo in the rat, Drug Metab. Dispos. 20(5):625-631 (1992). cited by other . Kobayashi and Taguchi, Fluorinated Vitamin D.sub.3 Analogs Syntheses and Biological Activites, in Biomedical Aspects of Fluorine Chemistry (R. Filler and Y. Kobayashi, eds.), Associated Scientific Publishers, Amsterdam, pp, 33 (1982). cited by other . Koblin et al., I-653 Resists Degradation in Rats, Anesth. Analg. 67(6):534-538 (1988). cited by other . Kollonitsch et al., Selective Inhibitors of biosynthesis of Aminergic Neurotransmitters, Nature 274(5674):906-908 (1978). cited by other . Kong et al., Comparisons of Anti-Human Immunodeficiency Virus Activites, Cellular Transport, and Plasma and Intracellular Pharmacokinetics of 3'-Fluoro-3'-Deoxythymidine and 3'-Azido-3'-Deoxythymidine, Antimicrob. Agents Chernother, 36(4):808-818 (1992). cited by other . Kripalani et al., Metabolism of Triamcinolone Acetonide-21-Phosphate in Dogs, Monkeys, and Rats, J. Pharm. Sci. 64(8):1351-1359 (1975). cited by other . Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989;45:28-33. cited by other . Kropp et al., Meabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I Antimicrob. Agents Chemother. 22(1):62-70 (1982). cited by other . Kuo et al., Effects of Combined Probucol-Colestipol Treatment for Familial Hypercholesterolemia and Coronary Artery Disease, Am. J. Cardiol. 57:43H-48H (1986). cited by other . Landsberg, Can Entropy and "Order" Increase Together? Physics Letters 102A(4):171-173 (1984). cited by other . Landsberg, Is Equilibrium Always an Entropy Maximum? J. Stat. Physics 35(1/2):159-169 (1984). cited by other . Lees et al., Therapy of Hypercholesterolemia with Mevinolin and Other Lipid-Lowering Drugs, Arteriosclerosis 6:544 (1986). cited by other . Lehninger et al., Principles of Biochemistry, Second Edition (Worth Publishers, NY), Table of Contents (1993). cited by other . Li et al., Catechol Formation of Fluoro--and Bromo-Substituted Estradiols by Hamster Liver Microsomes. Evidence for Dehalogenation, Mol. Pharmacol. 27(5):559-565 (1985). cited by other . Liehr, 2-Fluoroestradiol, Separation of Estrogenicity from Carcinogenicity, Mol. Pharmacol. 23(2)278-281 (1983). cited by other . Lien, Structure-Absorption-Distribution Relationships: Significance for Drug Design, in Drug Design, vol. V, (Ariens, Ed.) Academic Press, NY, pp. 81-132 (1975). cited by other . Lloyd-Jones et al., Heart Disease and Stroke Statistics--2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, pp. e22-e181 (Jan. 27, 2009) (downloaded from circ.ahajournals.org on Apr 14, 2009). cited by other . Low and Castagnoli, Drug Biotransformations, in Burger's Medicinal Chemistry, 4th Ed., Part I, The Basis of Medicinal Chemistry, (Wolff, ed.), John Wiley & Sons, NY, pp. 108-226 (1980). cited by other . Low and Castagnoli, Metabolic Changes of Drugs and Related Organic Compounds, in Wilson and Gisvolds Textbook of Organic Medicinal and Pharmaceutical Chemistry, 9th Ed., Ch. 3, (Delgado and Remers, Eds.), pp. 45-127 (1991). cited by other . Mabuchi et al., Reduction of serum cholesterol in heterozygous patients with familial hyperchalesterolemia, New Eng. J. Med, 308:609-613 (1983). cited by other . Malloy et al., Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia, Ann. Intern. Med., 107:616-623 (1987). cited by other . Mann et al., Probucol in patients resistant to the lipid lowering effects of cholestyramine, Lancet Feb. 21;1(8217):450-451 (1981). cited by other . Mann, Modern Methods for the Introduction of Fluorine into Organic Molecules: An Approach to Compounds with Altered Chemical and Biological Activities, Chem. Soc. Rev. 16:381-436 (1987). cited by other . Manuel et al., Burden of cardiovascular disease in Canada, Can J. Cardiol. 19(9):997-1004. cited by other . March, Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Fourth Edition (Wiley 1992) University of Michigan, Table of Contents. cited by other . Masood et al., 2'-Fluoro-2,3'-Dideoxyarabinosyladenine: A Metabolically Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine, Mol. Pharmacol, 37(4):590-596 (1990). cited by other . Matthes et al., Phosphorylation, Anti-HIV Activity and Cytotoxicity of 3'-Fluorothymidine, Biochem. Biophys. Res. Commun. 153(2):825-831 (1988). cited by other . Mauro and Tuckerman, Ezetimibe for Management of Hypercholesterolemia, Ann. of Phormacother. 37:839-848 (2003). cited by other . Mazze et al., Inorganic Fluoride Nephrotoxicity: Prolonged Enflurane and Halothane Anesthesia in Volunteers, Anesthesiology 46(4):265-271 (1977). cited by other . Mazze et al., Methoxyflurane Metabolism and Renal Dysfunction: Clinical Correlation in Man, Anesthesiology 35(3):247-252 (1971). cited by other . Mazze et al., Renal Effects and Metabolism of Isoflurane in Man, Anesthesiology 40(6):536-542 (1974). cited by other . McCarthy et al., 4',5'-Unsaturated 5'-Fluoroadenosine Nucleosides: Potent Mechanism-Based Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase, J. Am. Chem. Soc. 111:1127-1128 (1989). cited by other . McCarthy, New Approaches to Atherosclerosis: An Overview, Med. Res. Rev. 13(2):139-159 (1993). cited by other . McGill et al., Natural History of Human Atherosclerotic Lesions, Atherosclerosis and its Origin, (Sandler and Bourne, eds.), pp. 39-65 (1963). cited by other . McKittrick et al., Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorg. & Med. Chem Lett. 6(16):1947-1950 (1996). cited by other . McKittrick et al., Synthesis of C3 Heteroatom-Substituted Azetidinones that display potent cholesterol absorption inihibitory activity, J. Med. Chem. 41(5):752-759 (1998). cited by other . Merck Manual of Diagnosis & Therapy, 25th Ed., Berkow (ed.), Merck & Co., Inc., at p. 2430.--"pharmacokinetics" (1987). cited by other . Merriam-Webster's New Collegiate Dictionary, 8th ed., Merriam-Webster, Inc.--"administering" (1981). cited by other . Michalek et al., Pharmacokinetics of TCDD in veterans of Operation Ranch Hand; 10-year-follow-up, Journal of Toxicology and Environmental Health 52(6):557-558 (1997). cited by other . Miller and Miller, The Carcinogenicity of Fluoro Derivatives of 10-Methyl-1,2-Benzanthracene. I. 3- and 4'-Monofluoro Derivatives, Cancer Res. 20:133-137 (1960). cited by other . Minagawa et al., Identification and Quantification of 6 .beta.-Hydroxydexamethasone as a Major Urinary Metabolite of Dexamethasone in Man, Steroids 47(2-3):175-188 (1986). cited by other . Molgaard et al., Long-term Efficacy and Safety of Simvastatin Alone and in Combination Therapy in Treatment of Hypercholesterolaemia, Atherosclerosis 91:S21-S28 (1991). cited by other . Montgomery et al., Synthesis and Biological Evaluation of 2-Fluoro-8-Azaadenosine and Related Compounds, J. Med. Chem. 26(10):1483-1489 (1983). cited by other . Morgan et al., Oxidative Dehalogenation of 2-Fluoro-17 .alpha.-Ethynyloestradiol in vivo. A Distal Structure-Metabolism Relationship of 17 .alpha.-Ethynylation, Biochem. Pharmacol. 44(9):1717-1724 (1992). cited by other . Morgan et al., The Metabolism of 2- and 4-Fluoro-17 .beta.-Oestradiol in the Rat and its Implications for Oestrogen Carcinogenesis, Biochem. Pharmacol. 43(5):985-993 (1992). cited by other . Morinelli et al., Difluorothromboxane A.sub.2 and Stereoisomers: Stable Derivatives of Thromboxane A.sub.2 with Differential Effects on Platelets and Blood Vessels, Proc. Natl. Acad. Sci. U.S.A. 86(14):5600-5604 (1989). cited by other . Murphy et al., Some Aspects of the Metabolism and Disposition of Betamethasone, Acta. Endocrinol. 45:498-508 (1964). cited by other . Murray-Rust, Intermolecular Interactions of the C-F Bond: The Crystallographic Environment of Fluorinated Carboxylic Acids and Related Structures, J. Am. Chem. Soc. 105:3206-3214 (1993). cited by other . Nagabhushan, T. L., Kandasamy, D., Tsai, H., Turner, W. N. & Miller, G. H. (1980). Novel class of chloramphenicol analogs with activity against chloramphenicol-resistant and chloramphenicol-susceptible organisms. In Current Chemotherapy and Infectious Disease, vol. 1, Proceedings of the 11th International Congress of Chemotherapy and the 19.sup.th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 1979 (Nelson, J. D. & Grassi, C, Eds), pp. 442-443. American Society for Microbiology, Washington, DC. cited by other . Napoli et al., 1 .alpha.-hydroxy-25-fluorovitamin D.sub.3: a potent analogue of 1 .alpha.,25-dihydroxyvitamin D.sub.3, Biochemistry 17(12):2387-2392 (1978). cited by other . Napoli et al., 1-Fluorovitamin D3, a vitamin D3 analogue more active on bone-calcium mobilization than on intestinal-calcium transport, Biochemistry 18(9):1641-1646 (1979). cited by other . Negishi et al., Palladium-Catalyzed Acylation of Oganozincs and Other Organometalics as a Convenien Route to Ketones,Tetrahedron Lett. 24(47):5181-5184 (1983). cited by other . Nelson et al., Does Ammonia Hydrogen Bond? Science 238(4834): 1670-1674 (1987). cited by other . Nikkari et al., The hyperlipidemic hamster as an atherosclerosis model, Artery 18(6)285-290 (1991). cited by other . Oguni et al., Stereoselective Synthesis of .beta.-Lactam Derivatives by Ultrasound Promoted Reformatskii Reaction, Chem. Abstracts No. 17, vol. 106:138174y (1987). cited by other . Packard et al., Combined drug therapy for familial hypercholesterolemia, Artery 7(4):281-289 (1980). cited by other . Park and Kitteringham, Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications, Drug Metab. Reviews 26(3):605-643 (1994). cited by other . Patani and LaVoie, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 96(8):3147-3176 (1996). cited by other . Peters et al., Biochemistry of Fluoroacetate Poisoning: The Isolation and Some Properties of the Fluoroticarboxylic Acid Inhibitor of Citrate Metabolism, Proc. Roy. Soc. B140:497-507 (1952). cited by other . Peters, Some Metabolic Aspects of Fluoroacetate Especially Related to Fluorocitrate, in Carbon Fluorine Compounds: Chemistry, Biochemistry & Biological Activies, A Ciba Foundation Symposium, (Elsevier Excerpta Medica North-Holland), Associated Scientific Publishers, Amsterdam, london, New York, pp. 55-76 (1972). cited by other . Pinedo and Petes, Fluorouracil: Biochemistry and Pharmacology, J. Clin. Oncol. 6(10):1653-1664 (1988). cited by other . Pohl et al., Neoantigens associated with halothane hepatitis, Drug Metab. Rev. 20(2-4):203-217 (1989). cited by other . Poston and Foreyt, Scientific and Legal Issues Fenfluramine/Dexfenfluramine Litigation, Tex. Med. 96(2):48-56 (2000). cited by other . Regardh et al., Plasma Levels and .beta.-Blocking Effect of Hydroxymetoprolol--Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5):471-479 (1979) (Abstract only). cited by other . Reifenrath et al., Synthesis and Biological Activity of Fluoroalkylamine Derivatives of Narcotic Analgesics, J. Med. Chem. 23(9):985-990 (1980). cited by other . Rekker and Mannhold, Calculation of Drug Lipophilicity--The Hydrophobic Fragmental Constant Approach (Jointly by VCH Verlagsgesellschaft, Weinhehn (Federal Republic of Germany) and VCH Publishers Inc., New York (USA)), Table of Contents (1992). cited by other . Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Arch. Intern. Med. 148:36-69 (1988). cited by other . Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part I, II Farmaco. 45(10):1043-1066 (1990). cited by other . Resnati, Aspects of the Medicinal Chemistry of Fluoroorganic Compounds. Part II, II Farmaco. 45(11):1137-1167 (1990). cited by other . Rice et al., Fluorine Probes for Investigating the Mechanism of Activation of Indeno[1,2,3-cd] Pyrene to a Tumorigenic Agent, Carcinogenesis 11(11):1971-1974 (1990). cited by other . Ridker et al., Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of Rosuvastatin: a prospective study of the JUPITER trial, Lancet 373(9670):1175-82 (2009). cited by other . Ridker et al., Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New Eng. J. Med., 359(21):2195-2207 (2008). cited by other . Rietjens and Vervoort, Bioactivation of 4-Fluorinated Anilines to Benzoquinoneimines as Primary Reaction Products, Chem. Biol. Interact. 77(3):263-281 (1991). cited by other . Rifai et al., Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years, Clin. Chem. 50:10:1861-1870 (2004). cited by other . Roman et al., Renal Tubular Site of Action of Fluoride in Fischer 344 Rats, Anesthesiology 46(4):260-264 (1977). cited by other . Rosenblum et al., Discovery of 1-(4- Fluoropheny1)-(3R)43-(4-Fluorophenyl)-(3S)-Hydroxypropylk-(4S)-(4- Hydroxyphenyl)-2-Azetidinone (SCH 58235), A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, J. Med. Chem. 41(6):973-980 (1998). cited by other . Rosenblum et al., Discovery of SCH 58235, a potent orally active inhibitor of cholesterol absorption, XII International Symposium on Drugs Affecting Lipid Metabolism, Abstract, p. 61 (1995). cited by other . Roth et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase. I. Identification and Structure-Activity Relationships of a Novel Series of Fatty Acid Anilide Hypocholesterolemic Agents, J. Med. Chem. 35(9):1609-1617 (1992). cited by other . Sandberg and Slaunwhite, Differences in Metabolism of Prednisolone-C.sup.14 and Cortisol-C.sup.14, J. Clin. Endocrinol. Metab. 17(9):1040-1050 (1957). cited by other . Scandinavian Simvastatin Survival Study Group, Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S), Lancet 344(8934):1383-1389 (1994). cited by other . Secrist et al., 2-Fluoroformycin and 2-Aminoformycin, Synthesis and Biological Activity, J. Med. Chem. 28(11):1740-1742 (1985). cited by other . Serway, Physics For Scientists & Engineers, Third Edition, (Updated Version), vol. 1, Saunders Golden Sunburst Series (Saunders College Publishing and Harcourt Brace College Publishers, Philadelphia), Table of Contents (1992). cited by other . Shankar et al., Synthesis of an Optically Pure 3-Unsubstituted .beta.-Lactam Using an Asymmetric Reformatsky Reaction and its Conversion to Cholesterol Absorption Inhibitors, Tet. Lett. 37(24),4095-4098 (1996). cited by other . Shetty and Nelson, Chemical Aspects of Metoprolol Metabolism. Asymmetric Synthesis and Absolute Configuration of the 3-[4-(1-Hydroxy-2-methoxyethyl)phenoxy]-1-(isopropylamino)-2-propanols, the Diastereomeric Benzylic Hydroxylation Metabolites, J. Med. Chem. 31(1):55-59 (1988). cited by other . Silverman, Lead Modification: Drug Design and Development, in The Organic Chemistry of Drug Design and Drug Action, 2.sup.nd Ed., Sec. 2.2, pp. 29-32 (2004). cited by other . Sliskovic and White, Therapeutic Potential of ACAT Inhibitors as Lipid Lowering and Anti-Atherosclerotic Agents, Trends Pharmacol. Sci. 12:194-199 (1991). cited by other . Sommariva et al., Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia, Int. J. Clin. Pharmacol, Ther. Taxicol., 24(9):505-510 (1986). cited by other . Stahle and Ljungdahl-Stahle, Pharmacokinetics and Extracellular Distribution to Blood, Brain, and Muscle of Alovudine (3'-Fluorothymidine) and Zidovudine in the Rat Studied by Microdialysis, J. Acquir. Immune. Defic. Syndr. 6(5):435-439 (1993). cited by other . Stary et al., A Definition of Initial, Fatty Streak, and Intermediate Lesions of Atherosclerosis. A Report From the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Arterioscler. Thromb. Vasc. Biol. 14:840-856 (1994). cited by other . Stedman's Medical Dictionary, www.medilexicon.comimedicaldictionary.php. Lippincott Williams & Wilkins (2006)--"prodrug". cited by other . Stein et al., Achieving Lipoprotein Goals in Patients at High Risk with Severe Hypercholesterolemia: Efficacy and Safety of Ezetimibe Co-administered with Atorvastatin. Am Heart J 2004; 148(3),447-55. cited by other . Stein et al., Lavastatis alone and in combination with resin in severe primary hypercholesterolemia, Arteriosclerosis 7:513A (1985). cited by other . Stein et al., Treatment of severe familial hypercholesterolemia with Lovastatin, resin and niacin, Arteriosclerosis 7:517A (1987). cited by other . Steinberg, An interpretive history of the cholesterol controversy: part 1, J. Lipid Res. 45:1583-1593 (1994). cited by other . Subcommittee on the National Halothane Study, "Summary of the National Halothane Study" J. Am. Med. Assoc. 197(10):121-134 (1966). cited by other . Sybertz et al., SCH 48461, a novel inhibitor of cholesterol absorption, Atherosclerosis X, Workshop Abstracts, p. 89, Montreal, Oct. 10, 1994. cited by other . Tagg et al., Metabolic studies of tolbutamide in the rat, Biochemical Pharmacology 16(1):143-53 (1967). cited by other . Takahashi et al., Crystal structure of the covalent complex formed by a peptidyl-.alpha.-.alpha.-difluoro-.beta.-keto amide with porcine pancreatic elastase at 1.78.ANG. resolution, J. Am. Chem. Soc. 111:3368-3374 (1989). cited by other . Tanaka et al., 26,26,26,27,27,27-Hexafluoro-1,25-Dihydroxyvitarnin D.sub.3: A Highly Potent, Long-Lasting Analog of 1,25- Dihydroxyvitamin D.sub.3, Arch. Biochem. Biophys. 229(1):348-354 (1984). cited by other . Taylor et al., The metabolic fate of prazosin, Xenobiotica 7(6):357-64 (1977). cited by other . Taylor, Allen J. et al., Extended Release Niacin or Ezetimibe and Carotid Intima-Media Thickness, New Engl. J. Med. 361(22)2113-2122 (2009). cited by other . Thornber, Isosterism and molecular modification in drug design, Chem. Soc. Review, 18(4),563-580 (1979). cited by other . Thummel et al., Human Liver Microsomal Enflurane Defluorination Catalyzed by Cytochrome P-450 2E1 Drug Metab. Dispos. 21:350-357 (1993). cited by other . Tidwell, Thomas T., Schiff Bases, and a Century of .beta.-Lactam Synthesis, Angew. Chem. Int. Ed. 47:1016-1020 (2008). cited by other . Tingle et al., Influence of Glutathione Conjugation on the Immunogenicity of Dinitrophenyl Derivatives in the Rat, Int. Arch. Allergy Appl. Immunol. 91(2):160-165 (1990). cited by other . Tocco et al., Physiological Disposition and Metabolism of 5-(2',4' -Difluorophenyl)Salicyclic Acid, a New Salicylate, Drug Metab. Dispos. 3(6):453-466 (1975). cited by other . Topliss and Martin, Utilization of Operational Schemes for Analog Synthesis in Drug Design, in Drug Design (Ariens, ed.), ch. 1, pp. 1-21 (1975). cited by other . Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem. 15(10):1006-1011 (1972). cited by other . Trivedi et al., Inhibitors of Acyl-CoA: Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N-[(1- Phenylcyclopentyl) Methyl]Ureas with Enhanced Hypocholesterolemic Activity, J. Med. Chem. 37(11):1652-1659 (1994). cited by other . Tsushima et al., Fluorine-Containing Amino Acids and Their Derivatives, 4. Synthesis and Antibacterial Activity of Threo and Erythro 1-Fluorodehydroxylated Chloramphenicol Analogues, J. Med. Chem. 28(2):253-256 (1985). cited by other . van Heek et al., Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, British J. Pharm, 129:1748-1754 (2000). cited by other . van Heek et al., Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats, British J. Pharm. 138:1459-1464 (2003). cited by other . van Heek et al., In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH4846I, J. Pharm. and Exp. Ther. 283(1):157-163 (1997). cited by other . van Heek et al., Isolation and identification of the active metabolite(s) of SCH48461 and possible in vivo mechanism of action for their inhibition of cholesterol absorption, XII Int'l Symp. ON Drugs Affecting Lipid Metabolism, Nov. 7. 1995, Houston, TX. cited by other . van Heek et al., The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys, Eur. J. Pharmacol. 415(1):79-84 (2001). cited by other . Velican and Velican, Coronary arteries in children up to the age of ten years, II. Intimal thickening and its role in atherosclerotic involvement, Med. Intern, 14:7-24 (1976). cited by other . Villines et al., The Arbiter 6-Halts Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration, J. Am. Coll. Cardiol. 55(24)1-6(2010). cited by other . Waters et al., Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients with Stable Coronary Disease in the TNT (Treating to New Targets) Study, J. Am Coll Card, 48(9)1793-1799 (2006). cited by other . Weeks et al., A Comparison of the Molecular Structures of Six Corticosteroids, J. Am. Chem. Soc. 95(9):2865-2868 (1973). cited by other . Weisweiler and Schwandt, Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia, Lancet 1212-1213 (Nov. 22, 1986). cited by other . Welch and Eswarakrishnan, Fluorine in Bioorganic Chemistry, John Wiley & Sons, NY, pp. 1-261 (1991). cited by other . Welch, Advances in the Preparation of Biologically Active Organofluorine Compounds, Tetrahedron 43(14):3123-3197 (1987). cited by other . Wermuth, Chemical modifications of medications with a view to the improvement of their action, Agressologie 7(3):213-219 (1966). cited by other . Wilhelm et al., 6-Fluoro-Vitamin D.sub.3: A New Antagonist of the Biological Actions of Vitamin D.sub.3 and its Metabolites which Interacts with the Intestinal Receptor for 1 .alpha.,25(OH).sub.2-Vitamin D.sub.3, Arch. Biochem. Biophys. 233(1):127-132 (1984). cited by other . Williams, Drug Metabolism, in Principles of Medicinal Chemistry, Third Ed., Ch. 5, pp. 79-117 (Foye, ed.), Lea & Febinger, Philadelphia (1989). cited by other . Wirebaugh et al., A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin, Pharmacotherapy 12(6):445-450 (1992). cited by other . Wolff et al., Substrate Specificity of Human Liver Cytochrome P-450 Debrisoquine 4-Hydroxylase Probed Using Immunochemical Inhibition and Chemical Modeling, Cancer Res. 45:2116-2122 (1985). cited by other . Wood et al., The Effect of Cimetidine on Anesthetic Metabolism and Toxicity, (1986) Anesth. Analg. 65(5):481488. cited by other . Woodrow, Essentials Of Pharmacology For Health Occupations, 4th Ed., Delmar, Thomson Learning, Ch. 7, pp. 87-139--"right amount" (2002). cited by other . Wu et al., A Novel One-Step Diastereo--and Enantioselective Formation of Trans-Azetidinones and its Application to the Total Synthesis of Cholesterol Absorption Inhibitors, J. Org. Chem. 64(10):3714-3718 (1999). cited by other . Yumibe et al., Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyoratadine by CYP3A4 and CYP2D6, Biochem. Pharm. 51:165-172 (1996). cited by other . Zia-Amirhosseini, Bioactivation by Glucuronide-Conjugate Formation, Adv. Pharma, 27:385-397 (1994). cited by other . Complaint against Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Statement 7.1 disclosure# 2 Civil Cover Sheet # 3 Summons Glenmark, USA# 4 Summons Glenmark Ltd.)(mn, ) (Entered: Mar. 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Answer to Complaint, Counterclaim against all plaintiffs by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Corporate Disclosure Statement)(Walsh, Liza) (Entered: May 23, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Corrected Answer to Complaint, Counterclaim against Schering Corporation, MSP Singapore Company LLC by Glenmark Pharmaceuticals, Inc. USA Ltd..(Walsh, Liza) (Entered: Jun. 7, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Answer to Counterclaim of Glenmark Pharmaceuticals, Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Answer to Counterclaim of Glenmark Pharmaceuticals, Inc. USA. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Jul. 3, 2007), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Liza M. Walsh to the Honorable Jose L. Linares. (Attachments: # 1 Brief in Support of Proposed Claim Interpretations# 2 Declaration of Agnes Antonian # 3 Text of Proposed Order # 4 Certificate of Service)(Walsh, Liza) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief. (Attachments: # 1 Brief# 2 Proposed Order# 'Certification of Service# 4 Krause Declaration, Ex. A# 5 Krause Declaration, Ex. B# 6 Krause Declaration, Ex. C Part 1# 7 Krause Declaration, Ex. C Part 2# 8 Krause Declaration, Ex. C Part 3# 9 Krause Declaration, Ex. D Part 1# 10 Krause Declaration, Ex. D Part 2# 11 Krause Declaration, Ex. D Part 3# 12 Krause Declaration, Ex. D Part 4# 13 Krause Declaration, Ex. E Part 1# 14 Krause Declaration, Ex. E Part 2# 15 Krause Declaration, Ex. E Part 3# 16 Krause Declaration, Ex. E Part 4# 17 Krause Declaration, Ex. E Part 5# 18 Krause Declaration, Ex. E Part 6# 19 Krause Declaration, Exs. F-G# 20 Krause Declaration, Exs. H-O# 21 Krause Declaration, Exs. P-Q)(Halper, Jason) (Entered: Jan. 14, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Brief In Response To Plaintiffs' Proposed Claim Interpretations filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Certification of Service)(Walsh, Liza) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Brief in Opposition to Defendants' Opening Markman Brief filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Supplemental Krause Declaration, # 2 Supp. Krause Declaration, Exs. R-V, # 3 Supp. Krause Declaration, Exs. W-Y, # 4 Certification of Service)(Halper, Jason) (Entered: Feb. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . First Amended Answer to Complaint by Glenmark Pharmaceuticals, Inc.USA.(Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . First Amended Answer to Complaint by Glenmark Pharmaceuticals Ltd. (Walsh, Liza) (Entered: Mar. 10, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES). cited by other . Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals, Inc. USA by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Answer to Counterclaim Amended Counterclaim of Glenmark Pharmaceuticals Ltd. by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Certification of Service)(Halper, Jason) (Entered: Apr. 9, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Plaintiffs regarding July 29 Markman Hearing re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 1, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Defendants In Response to Plaintiffs' Aug. 1 Suppl Briefing On Claim Construction. (Ruiz, Hector) (Entered: Aug. 7, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Plaintiffs in Reply to Glenmark's Aug. 6, 2008 Letter re Letter from Plaintiffs Enclosing Plaintiffs' Opening Claim Construction Brief, (Halper, Jason) (Entered: Aug. 8, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Defendants in Response to Plaintiffs' Aug. 8, 2008 Letter On Claim Construction Issues. (Ruiz, Hector) (Entered: Aug. 12, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Opinion. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD,) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Order granting Plaintiff's appl. For claims construction.. Signed by Judge Jose L. Linares on Sep. 15, 2008. (DD, ) (Entered: Sep. 16, 2008), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) by Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Statement of Undisputed Material Facts, # 2 Confidential Memorandum of Law [Redacted], # 3 Confidential Declaration of Robert L. Jacobson [Redacted], # 4 Confidential Exhibits A-E [Redacted], # 5 Confidential Exhibits F-K [Redacted], # 6 Proposed Order, # 7 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD,). (Entered: Jul. 1, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) by Glenmark Pharmaceuticals, Inc. USA, Glenmark Pharmaceuticals Ltd. (Attachments: #1 Statement of Material Facts Not in Dispute, # 2 Memorandum of Law In Support of Summary Judgment, # 3 Declaration of George Hykal, # 4 Exhibits A through B to George Hykal Declaration, # 5 Exhibits C through E to George Hykal Declaration, # 6 Exhibits F through H to George Hykal Declaration, # 7 Proposed Order, # 8 Certificate of Service)(Walsh, Liza) Modified on Apr. 12, 2010 (DD, ). (Entered: Jul. 8, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Brief in Opposition re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Rule 56.1 Responsive Statement of Material Facts, # 2 Suh Declaration, # 3 Suh Declaration Exhibits (Redacted), # 4 Proposed Order, # 5 Certification of Service)(Halper, Jason) (Entered: Jul. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Brief in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Local Rule 56.1 Statement of Facts, # 2 Proposed Order, # 3 Certification of Service)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Certification in Opposition re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Declaration of James Suh filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exibits 1-4, # 2 Exhibits 5-16, # 3 Exhibits 17, # 4 Exhibit 18 (Part 1), # 5 Exhibit 18 (Part 2) # 6 Exhibits 19-21, # 7 Exhibit 22, # 8 Exhibits 23-25, # 9 Exhibit 26 (Part 1), # 10 Exhibit 26 (Part 2), # 11 Exhibit 26 (Part 3), #12 Exhibit 26 (Part 4), # 13 Exhibits 27-29, # 14 Exhibits 30-32, # 15 Exhibit 33, # 16 Exhibit 34, # 17 Exhibits 35-40, # 18 Exhibits 41-46, # 19 Exhibit 47 (Part 1), # 20 Exhibit 47 (Part 2), # 21 Exhibits 48-52, # 22 Exhibit 53 (Part 1), # 23 Exhibit 53 (Part 2), #24 Exhibit 53 (Part 3), # 25 Exhibits 54-60, # 26 Exhibit 61 (Part 1), # 27 Exhibit 61 (Part 2), # 28 Exhibits 62-63, # 29 Exhibit 64, # 30 Exhibits 65-69)(Halper, Jason) (Entered: Aug. 5, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. To Suppl. Stmn. of Disputed Facts (Redacted), # 2 Decl. of Jay Lessler, # 3 Exhibit A pp. 1-29, # 4 Exhibit A pp. 30-59, # 3 : Exhibit A pp. 60-89, # 6 Exhibit A pp. 90-112, # 7 Exhibit B, # D, Exhibit C)(Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Reply Brief to Opposition to Motion re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Amended Reply Brief filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Revised Declaration of Jay P. Lessler, # 2 Lttr. to Judge Linares Encl. Amended Reply and Revised Decl.)(Walsh, Liza) (Entered: Aug. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Reply Brief to Opposition to Motion re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd.. (Attachments: # 1 Resp. to Pltffs.' Stmn. of Disputed Facts (Redacted))(Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Pretrial Memorandum by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Certificate of Service)(Halper, Jason) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re MOTION for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) (Attachments: # 1 Appendix A)(Lessler, Jay) (Entered: Jan. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Plaintiffs in Response to Defendants' Notice of Supplemental Authority re Notice by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) of Supplemental Authority in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue). (Halper, Jason) (Entered: Jan. 14, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Order withdrawing Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); withdrawing Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting); Signed by Judge Jose L. Linares on Mar. 30, 2010. (DD, ) (Entered: Mar. 31, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Order Reinstating re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) filed by Glenmark Pharmaceuticals, Inc. USA, Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. Signed by Judge Jose L. Linares on Apr. 9, 2010. (DD, ) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Opinion. Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Order granting Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue); denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting). Signed by Judge Jose L. Linares on Apr. 19, 2010. (jd, ) (Entered: Apr. 19, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Brief in Support of Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13, # 2 Text of Proposed Order, # 3 Certificate of Service)(Halper, Jason) (Entered: Apr. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Brief in Opposition re Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13 filed by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc. USA. (Attachments: # 1 Proposed Order, # 2 Certification of Service)(Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Letter from Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. regarding Plaintiffs' Motion for Reconsideration of the Court's Order Granting Defendants' Motion for Summary Judgment of Invalidity of Claims 10 through 13.. (Walsh, Liza) (Entered: May 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Order Vacating re Order granting on Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue), Order on denying Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Apr. 19, 2010 Opinion. Signed by Judge Jose L. Linares on May 10, 2010. (DD, ) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Consent Judgment. Signed by Judge Jose L. Linares on May 10, 2010. (DD) (Entered: May 10, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: #1 Summons1, # 2 Summons2, # 3 Civil Cover Sheet)(Id) (Entered: Dec. 22, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Motion to Dismiss for Failure to State a Claim Upon Which Relief May Be Granted and/or for Lack of Subject Matter Jurisdiction by Mylan Inc. (Attachments: #1 Brief in support of Mylan, Inc.'s Motion to Dismiss, # 2 Declaration of Andrew Kozusko in support of Mylan, Inc.'s Motion to Dismiss, # 3 Text of Proposed Order, # 4 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Answer to Complaint, Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Feb. 12, 2010), U.S. District Court for ihe District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Amended Answer to Complaint, Separate Defenses, Amended Counterclaim and Jury Demand against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Mar. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Stipulation of Dismissal as to Defendant Mylan Inc. by MSP Singapore Company LLC, Schering Corporation. (Attachments: # 1 Letter)(Halper, Jason) (Entered: Mar. 11, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Stipulation and Order terminating Deft. Mylan Inc., etc., Signed by Judge Jose L. Linares on Mar. 16, 2010. (dc, ) (Entered: Mar. 18, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Answer to Counterclaim by MSP Singapore Company LLC, Schering Corporation.(Halper, Jason) (Entered: Apr. 7, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Civil Cover Sheet)(dr) (Entered: Mar. 4, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Stipulation of Dismissal as to Defendant Teva Pharmaceutical Industries Ltd. by MSP Singapore Company LLC, Schering Corporation. (Halper, Jason) (Entered: Mar. 30, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Stipulation and Order dismissing action as to deft. Teva Pharmaceutical Industries, Ltd. Signed by Judge Jose L. Linares on Mar. 31, 2010. (nr) (Entered: Apr. 5, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Corrected Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: Apr. 12, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Amended Answer to Complaint by Teva Pharmaceuticals USA, Inc. (Patunas, Michael) (Entered: May 3, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-01058 (JLL/ES)). cited by other . Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 16, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC). cited by other . Answer to Complaint with Jury Demand , Separate Defenses, Counterclaim against MSP Singapore Company LLC, Schering Corporation by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Certificate of Service)(Calmann, Arnold) (Entered: Jul. 28, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-03085-JLL-CCC). cited by other . Complaint against Impax Laboratories, Inc., filed by Schering Corporation, MSP Singapore Company, LLC. (Attachments: # 1 EXH A, # 2 EXH B, # 3 EXH C, # 4 Civil Cover Sheet, # 5 Summons)(dr, ) (Entered: Aug. 24, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04270-JLL-CCC). cited by other . Complaint against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A to Complaint, # 2 Exhibit B to Complaint, # 3 Exhibit C to Complaint, # 4 Summonsl, # 5 Summons2, # 6 Civil Cover Sheet)(Id, ) (Entered: Sep. 2, 2010), U.S. District Court for the District of New Jersey (Civil Action No. 2:10-cv-04473-JLL-CCC). cited by other . Complaint against Mylan Inc., Mylan Pharmaceuticals Inc., filed by Schering Corporation, MSP Singapore Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Cover letter)(kd) (Entered: Dec. 18, 2009), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK). cited by other . Notice of Voluntary Dismissal by MSP Singapore Company LLC, Schering Corporation (Attachments: # 1, Attachment Exhibit 1)(Simmerman, Frank) (Entered: Apr. 15, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:09-cv-00167-IMK). cited by other . Complaint against Mylan Pharmaceuticals, Inc. and Mylan Inc. filed by Schering Corporation and MSP Singapore Company LLC., (filed Jun. 29, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK). cited by other . Notice of Voluntary Dismissal by MSP Singapore Company, LLC, Schering Corporation (Attachments: # 1 Exhibit, Exhibit One)(Simmerman, Frank) (Entered: Aug. 19, 2010), U.S. District Court for the Northern District of West Virginia (Civil Action No. 1:10-cv-99-IMK). cited by other . Complaint; summons issued against Impax Laboratories, Inc., Filed by Schering Corporation, MSP Singapore Company LLC. (slh) (Filed on Aug. 20, 2010) (Entered: Aug. 23, 2010), U.S. District Court for the Northern District of California (Civil Action No. 3:10-cv-03719-JSW). cited by other . Deposition Transcript of Sundeep Dugar, Ph.D., dated May 2, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Nathan Yumibe, dated May 9, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Dr. Wayne Vaccaro, dated Jun. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Hearing Transcript before the Honorable Jose L. Linares (Markman Hearing), dated Jul. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Kevin Alton, dated Sep. 9, 2008, U.S. District Court for the District of New Jersey (Civil Action no. 07-cv-1334 {JLL/ES)). cited by other . Deposition Transcript of Margaret Van Heek, dated Sep. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Duane Burnett, dated Sep. 25, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Plaintiffs' Responses to Glenmark's Second Set of Interrogatories (Nos. 17-21), dated Sep. 25, 2008, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition 'Transcript of Harry Davis, dated Oct. 14, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Adriano Afonso, dated Oct. 21, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of James Nelson, dated Oct. 29, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of James Nelson, dated Oct. 30, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Cecil B. Pickett, dated Nov. 14, 2008. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Stuart B. Rosenblum, dated Dec. 4, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Stuart B. Rosenblum, dated Dec. 5, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of John Clader, Ph.D, dated Dec. 11, 2008, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Anita Magatti, dated Jan. 7, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Dorothy Auth, dated Jan. 9, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Deposition Transcript of Stuart Rosenbaum, dated Feb. 10, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of Clayton Heathcock, Ph.D., dated Feb. 25, 2009, U.S, District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of Dr. Ronald Hines, dated Feb. 27, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of Richard Bruce van Breernen, Ph.D., dated Mar. 2, 2009, U.S District Court for the District of New Jersey (Civil Action No. 07-cv-1337 (JLL/ES)). cited by other . Expert Report of Paul Ortiz de Montellano, Ph.D., dated Mar. 2, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Amended Responses to Plaintiffs' Interrogatories (Nos. 1-17), dated Mar. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of F. Peter Guengerich, dated Apr. 16, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of Christopher A. Vellturo. Ph.D., dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of Stephen G. Kunin, Esq. , dated Apr. 17, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/Es)). cited by other . Expert Report of Ronald G. Brisbois, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of W. Virgil Brown, M.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Expert Report of William R. Roush, Ph.D., dated Apr. 20, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Rebuttal Expert Report of Clayton Heathcock, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Rebuttal Expert Report of Ronald N. Hines, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Rebuttal Expert Report of Paul Ortiz de Montellano, dated May 8, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Rebuttal Expert Report of Jesse David, dated May 8, 2009. U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 1, dated May 11, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Supplemental Expert Report of Ronald G. Brisbois, Ph.D., dated May 22, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Statement of Material Fact in Support re Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 10, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07- cv-1334 (JLL/ES)). cited by other . Statement of Material Fact in Support re Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting) Resp. to Plaintiffs' Stmnt. of Disputed Material Facts (Confidential) filed by Glenmark Pharmaceuticals Ltd.. (Walsh, Liza) (Entered: Aug. 21, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.'s Supplemental Response To Plaintiffs' Interrogatory No. 4, dated Nov. 6, 2009, U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Trial Brief Defendants' (Filed Under Seal) by Glenmark Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Inc.USA. (Attachments: # 1 Certificate of Service)(Lessler, Jay) (Entered: Dec. 14, 2009), U.S. District Court for the District of New Jersey (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Final Pretrial Order, U.S. District Court for the District of New Jersey (redacted for Glenmark confidential information and personal information of witnesses), signed Mar. 11, 2010 (Civil Action No. 07-cv-1334 (JLL/ES)). cited by other . Joint Claim Construction and PreHearing Statement, dated Jul. 23, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-0v-06383 (JLL/ES)). cited by other . Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-3), dated Jul. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Plaintiffs' Response and Objections to Defendant Mylan Pharmaceuticals Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-11), dated Jul. 30, 2010, U.S. District Court for the District of new Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Transcript of Proceedings held on Aug. 12, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Transcript of Proceedings held on Sep. 8, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Defendant Mylan Pharmaceuticals Inc.'s Amended Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6 (redacted for Mylan confidential information), dated Sep. 9, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Letter from Plaintiffs Schering Corporation and MSP Singapore Company LLC to Judge Esther Salas seeking Modification of Proposed Claim Constructions Provided inJoint Claim Construction and Prehearing Statement (Proposed Order attached), dated Sep. 14, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Transcript of Proceedings held on Sep. 15, 2010, before Judge Esther Salas, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Declaration of Antonio M. Gotto, dated Sep. 29, 2010, U.S. District Court cm the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Declaration of Gerald S. Brenner, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES). cited by other . Declaration of James Suh in Support of Plaintiffs' Opening Claim Construction Brief, dated Sep. 29, 2010, U.S District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Declaration of Srilakshmi M. Ravi, dated Sep. 29, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Mylan's Opening Claim Construction Brief (Redacted), dated Sep. 30, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Brief in Response to Defendant's Opening Markman Brief filed by MSP Singapore Company LLC, Schering Corporation (Redacted) (Attachments: # 1 Supplemental Declaration of James Suh, # 2 Supp. Suh Declaration, Exhibit 38, # 3 Supp. Suh Declaration, Exhibit 39, # 4 Supp. Suh Declaration, Exhibit 40, # 5 Supp. Suh Declaration, Exhibit 41 (Redacted)), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Declaration of Srilakshmi M. Ravi (Supplemental) by Mylan Pharmaceuticals Inc., (Attachments: # 1 Exhibit 36 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 2 Exhibit 37 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 3 Exhibit 38 to the Declaration (Supplemental) of Srilakshmi M. Ravi, # 4 Exhibit 39 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Brief--Mylan's Responsive Claim Construction Brief filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 40 to the Declaration (Supplemental) of Srilakshmi M. Ravi), dated Nov. 19, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 09-cv-06383 (JLL/ES)). cited by other . Defendant Mylan Pharmaceuticals Inc.'s Answer To Plaintiffs' Complaint, Separate Defenses and Counterclaims, dated Jul. 28, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-03085 (JLL-ES)). cited by other . Defendant Impax Laboratories, Inc.'s Answer, Affirmative Defenses, Counterclaims and Jury Demand, dated Sep. 24, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)). cited by other . Plaintiffs' Answer to Impax Laboratories, Inc.'s Counterclaims, dated Oct. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04270 (JLL-CCC)). cited by other . Teva Pharmaceuticals USA, Inc.'s Answer to Complaint (Attachments: Certification Pursuant to Local Civile Rule 11.2), dated Oct. 7, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)). cited by other . Plaintiffs' Answer to Teva Pharmaceuticals USA, Inc.'s Counterclaims, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)). cited by other . Stipulation regarding Teva Pharmaceutical Industries Ltd. And Order, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)). cited by other . Consent Judgment on Counterclaim, dated Nov. 15, 2010, U.S. District Court for the District of New Jersey (Civil Action No. 10-cv-04473 (JLL/ES)). cited by other . Schering Notice of Application for Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Oct. 17, 2008, Federal Court of Canada (Court File No. T-1610-08). cited by other . Deposition Transcript of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Statement for the Record in re Deposition of Leslie Z. Benet, Ph.D., dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Deposition of Neal Castagnoli, Ph.D., dated Nov. 6, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Deposition of Antonio M. Gotto, Jr., M.D., D. Phil., dated Nov. 23, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Cross Examination Transcript of Gary Thiessen, dated Sep. 15, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Cross-Examination transcript of Mark Wentland, dated Dec. 4, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Cross-Examination transcript of John W. Clader, dated Dec. 9, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of John D. Sutherland, dated Apr. 6, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of A. Louise McLean, dated Apr. 9, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Glenn Ikeda, dated Apr. 13, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Dr. John Clader (Inventor) re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jun. 26, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Gary Thiessen re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SSR/06-242; SOR/2008-211, dated Jun. 30, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Neal Castagnoli, Ph.D. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations. SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Leslie Z. Benet re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 2, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Sonia Atwell re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SSR/98-66; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Mark Wentland re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR199-379; SOR/06-242; SOR/2008-211, dated Jul. 3, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Affidavit of Antonio M. Gotta Jr., M.D., D.Phil. re: Application Under Section 55.2 of the Patent Act and Section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, as am. SOR/98-166; SOR/99-379; SOR/06-242; SOR/2008-211, dated Jul. 6, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Reply Affidavit of John D. Sutherland, dated Oct. 1, 2009, Federal Court of Canada (Court File No. T-1610-08). cited by other . Deposition Transcript of Dr. John Sutherland (Cross-examination), dated Oct. 20, 2009, Federal Court of Canada (Cout File No. T.1610-08). cited by other . Memorandum of Fact and Law of the Respondent NovoPharm Limited ("TEVA"), dated Mar. 29, 2010, Federal Court of Canada (Court File No. T-1610-08). cited by other . Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp,, and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to .sctn.505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act. dated Nov. 5, 2009. cited by other . Letter from Teva Pharmaceuticals USA, Inc. to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 200909 Concerning Ezetimibe/Simvastatin Tablets, 10 mg/80 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721, dated Feb. 19, 2010. cited by other . Letter from counsel for Mylan Pharmaceuticals Inc. to MSP Singapore Co., Schering Corp., and Merck & Co., Inc. re: Notification of Certification of Noninfringement and/or Invalidity for U.S. Patent Nos. 5,846,966 and RE37,712 Pursuant to .sctn.505(j)(2)(B)(ii) of the U.S Federal Food, Drug and Cosmetic Act, dated May 25, 2010. cited by other . Letter from Impax Laboratories, Inc. to MSP Singapore Co. LLC, Merck & Co., Inc. and Schering Corporation. re: Paragraph IV Patent Certification Notice for U.S. Patent Nos. RE37,712 and 5,846,966, dated Jul. 9, 2010. cited by other . Letter from Teva Pharmaceuticals USA, Inc, to Merck & Co, Inc., MSP Singapore Company, LLC and Schering Corporation re: Notice of ANDA No. 078724 Concerning Ezetimibe Tablets, 10 mg with Paragraph IV Certification Concerning U.S. Patent Nos. 5,846,966 and RE37,721 and 7,612,058, dated Jul. 20, 2010. cited by other . Arnerican Heart Association/American Stroke Association Report Dec. 2009, "Facts: Breaking Our Hearts: Still America's No. 1 Killer," formerly accessible at http://www.americanheart.org/presenter.jhdml?identifierequal3049018 (cited as document C32 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341). cited by other . Boersma et al., Role of Cytochromes P-450 and Flavin-Containing Monooxygenase in the Biotransformation of 4-Fluoro-N-Methylaniline, Drug Metab. Dispos. 21(2):218-230 (1993) (full copy) (cited in abstract form as document C52 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341). cited by other . Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated May 8, 1996 from file history of U.S. Appl. No. 08/257,593. cited by other . Davis, Harry R.; Declaration of Harry R. Davis under 37 C.F.R, 1.132 dated Jan. 27, 1997 from file history of U.S. Appl. No. 08/449,978. cited by other . Dollery et al., (eds) Therapeutic Drugs, vol. 1, Churchill Livingstone, Edinburgh (1991). cited by other . Dujovne et al., Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a Multicenter Dose-Ranging Study, J. Clin Pharmacology 41:70-78 (2001) (full copy) (cited in abstract form as document C106 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341). cited by other . Grundy et al., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation 110(2):227-239 (2004). cited by other . Hobbs et al., Pharmacokinetics of prazosin in man, J. Clin. Pharmacol. 18(8):402-6 (1978) (full copy) (cited in abstract form as document C143 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,3741). cited by other . Jackevicius, C. A. et al., "Long-term Trends in Use of and Expenditures for Cardiovascular Medications in Canada," Canadian Medical Association Journal, 181(1-2):E19-E28, Jul. 7, 2009 (cited as document C156 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341). cited by other . Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Robert F. Doerge, Ed., 8.sup.th Ed., J.B. Lippincott Company, pp. 55-127 (1982). cited by other . Low and Castagnoli, "Metabolic changes of drugs and related organic compounds," In Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Jaime N. Delgado and William A. Remers, Eds., 9.sup.th Ed., J.B. Lippincott Company, pp. 45-127 (1991). cited by other . Ortiz de Montellano, ed., Cytochrome P-450. Structure, Mechanism, and Biochemistry, Ch. 7, Part 3.5, Heteroaton Oxidation and Dealkylation, Plenum Press (1986). cited by other . Otto et al., Darstellung und Stereochemie von 3-.alpha.-Hydroxybenzyl)-1,4-diphenyl-2-azetidononen, Liebigs Ann. Chem., vol. 1983, issue 7, pp. 1152-1161 (Aug. 15, 1983) (cited as document C16 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341). cited by other . Physician's Desk Reference, 46.sup.th Ed., pp. 1538, 1559-1560 (1992). cited by other . Regardh et al., Plasma Levels and .beta.-Blocking Effect of Hydroxymetoprolol--Metabolite of Metopropol in the Dog, J. Pharm. and Biopharm. 7(5)471-479 (1979) (full copy) (cited in abstract from as document C235 in the Information Disclosure Statement dated Aug. 13, 2010 in U.S. Appl. No. 12/797,341). cited by other . Sybertz, E. J., et al., "SCH 48461, a novel inhibitor of cholesterol absorption,"Atherosclerosis X (proceedings of the 10th International Symposium on Atherosclerosis, Montreal, Quebec, Oct. 9-14, 1994), Pub. Elsevier; pp. 311-315, eds. Woodford, F.P. Davington, J. & Sniderman A. (cited as document C24 in the Information Disclosure Statement dated Jul. 7, 2010 in U.S. Appl. No. 12/797,341). cited by other . Simova, E. "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", Chemical Abstracts No. 15, vol. 86, Apr. 11, 1977, Abstract 106130h. cited by other . Otto et al., Stereochemistry of dehydration and halogenation of .alpha.R* and .alpha.S* isomeric 3-(.alpha.-hydroxybenzyl)-1,4-diphenyl=2-azetidinones, Chemical Abstracts No. 19, vol. 99, Nov. 7, 1983 abstract 158083h. cited by other . Nobuki, O. et al. "Stereoselective syntheses of .beta.-lactam derivatives by ultrasound promoted Reformatskii reaction" Chemical Abstracts No. 106, vol. 17, Apr. 27, 1977 abstract 138174y. cited by other . T. Durst et al., 1971, "Metallation of N-Substituted .beta.-Lactams. A Method for the Introduction of 3-Substituents into .beta.-Lactams" Canadian Journal of Chemistry, 50:3196-3201. cited by other . C. Allain et al., 1974, "Enzymatic Determination of Total Serum Cholesterol" Clinical Chemical, 20:470-475. cited by other . R. Mayrhofer et al. 1980. "Simple Preparation of 3-Benzylidene-2-azetilidinones" Synthesis, 247-248. cited by other . M. Hoekman et al., 1982, "Synthesis of Homologues of 4.5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Acid-Lactones", J. Agric. Food Chem., 30:920-924. cited by other . H. Otto et al., 1983, "Darstellung und Stereochemic von 3-(.alpha.-Hydroxybenzyl)-1,4-diphenyl-azetidononen", Liebigs Ann. Chem. 1152-1161. cited by other . G. George et al., 1985 "3-(T-Hydroxyethyl)-2-Azetidinones From 3-Hdyroxy-butyrates and N-Arylaldimines" Tetrahedron Letters, vol. 26, No. 33 pp. 3903-3906. cited by other . Hart et al., 1985 "An Enantioselective Approach to Carhapenen Antibodies: Formal Synthesis of (+)-Thienamycin" Tetrahedron Letters, vol. 26, No. 45 pp. 5493-5496. cited by other . Pantil. I. et al., 1986, "Synthesis of .beta.-Lactams from .alpha., .beta.-Unsaturated Sugar .delta.-Lactones" Heterocycles 34:1609-1617. cited by other . D. Roger Hlingworth, 1988, "An Overview of Lipid-Lower Drugs" Drugs 36:63:71. cited by other . Joseph L. Witztum, M.D., 1989, "CUrrent Approaches to Drug Therapy for the Hyercholesterolemic Patient" Circulation 80:1101-1114. cited by other . B. Ram et al., 1990, "Potential hypolipidemic agents:Part V.dagger.-Synthesis biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates.dagger-dbl." Indian Journal of Chemistry 29B:1134-1137. cited by other . Schnitzer-Polokoff, R. et al. 1991, "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma lipoprotein Composition in Hamsters" Comp. Biochem. Physiol. 99A:665-670. cited by other . Horie, M. et al. 1991, "Hypolipidemic effects of NB-598 in dogs" Atherosclerosis 88:183-192. cited by other . Baxter, A., 1992, "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo," The Journal of Biological Chemistry 267:11705-11708. cited by other . Summary Factile, May 1992, "Anti-Antherosclerotic Agents" Current Drugs Ltd. pp. A5-A23. cited by other . Harwood, H. James, 1993, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin .beta.-tigogenin cellobioside (CP-88818;tiqueside).sup.1 " Journal of Lipid Research 34:377-395. cited by other . Salisbury, B. et al., 1995, "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" Atherosclerosis 115:45-63. cited by other . Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", Biochemical Pharmacology 47:1545-1551. cited by other . Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibition on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", The Journal of Pharmacology and Experimental Therapeutics 272:156-163. cited by other . Clader, J.W. et al., 1995, "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" Journal of Medicinal Chemistry 38:1600-1607. cited by other . Sybertz, E. 1995, "SCH 48461, a novel inhibitor of cholesterol absorption" Atherosclerosis pp. 311-315. cited by other. |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.